- This event has passed.
Opportunities for Innovation in HPV-Related Disease
November 12, 2020 @ 2:00 pm - 3:15 pm EST
The Society for Women’s Health Research hosted a virtual public forum on the need for innovation in HPV-related disease screening and treatment for women. Human papillomavirus (HPV) — the most common sexually transmitted infection — can cause cervical, anal, vaginal, vulvar, and oropharyngeal cancers. Women deserve better than the limited and invasive treatment options currently available.
In this webinar, panelists discuss the innovations in research, policy, and education that are needed to improve health outcomes for women with HPV-associated cancers and pre-cancers.
This public webinar is a follow-up to SWHR’s expert roundtable earlier this year that sought to identify gaps in research, clinical practice, policy, and education for HPV-associated diseases.
PANELISTS
Kate Weissman
Kate Weissman
Kate Weissman is a four-year Stage 2B cervical cancer survivor and a Cervivor Ambassador serving as an advocate for the cervical cancer community. She also volunteers with the Alliance for Proton Therapy Access and the American Cancer Society Cancer Action Network, lobbying for the implementation of cancer-related policies that will help patients and their families. She lives in Boston with her husband, Matt, and fur baby, Giada, and is a proud aunt to a whole lot of nieces and nephews. She is the vice president of integrated project management at a public relations agency and an avid food enthusiast.
Mona Saraiya, MD, MPH
Mona Saraiya, MD, MPH
Dr. Mona Saraiya is a Medical Officer and Team Lead in CDC’s Division of Cancer Prevention and Control’s (DCPC’s) Epidemiology and Applied Research Branch. Prior to her current position, she was associate director of DCPC’s Office of International Cancer Control. Dr. Saraiya has also worked on domestic issues related to skin cancer epidemiology and cervical cancer prevention and control. Her cervical cancer and human papillomavirus (HPV) research portfolio includes an initiative to characterize the HPV-associated cancer burden in the United States, and adherence to cervical cancer screening guidelines, especially with newer technologies such as HPV testing.
She graduated from Rush Medical College, completed a Masters of Public Health at Emory School of Public Health, completed a residency in Preventive Medicine/Public Health, and is board certified by the American College of Preventive Medicine. Dr. Saraiya is an alumna of the Epidemic Intelligence Service program and has published more than 150 articles during her tenure at CDC.
Mark H. Einstein, MD, MS
Mark H. Einstein, MD, MS
Dr. Mark H. Einstein is Professor and Chair at the Department of Obstetrics, Gynecology, & Reproductive Health and Associate Dean of Clinical Research at Rutgers New Jersey Medical School. He currently serves as President of the ASCCP, the society for lower genital tract disorders.
Dr. Einstein is an internationally-renowned expert in gynecologic oncology, particularly for his clinical and research focus in cervical cancer and human papillomavirus (HPV). He has led numerous multi-institutional clinical trials in targeting HPV and cervical cancer as well as cervical cancer prevention. He has been active in translating clinical trial and translational data into clinical practices regarding cervical cancer prevention including as 1) a member of the Steering Committee for the ASCCP Cervical Screening and Management Guidelines, 2) a workgroup member of the American Cancer Society and the Society of Gynecologic Oncologists separate recommendations for HPV vaccines, 3) a consultant to the World Health Organization (WHO), developing their modules on the immunologic basis of HPV vaccines, and harmonizing with current cervical cancer screening, and 4) principal investigator for many U.S. and global therapeutic HPV-targeted therapy trials.
